The EGF-receptor (EGFR) has become an important target in clinical oncology, and EGFR-targeting kinase inhibitors and monoclonal antibodies are routinely used in the treatment of lung cancer, head and neck cancer, and colorectal cancer (Guardiola et al., 2019). Here, EGFR is linked to lung cancer.